376592-93-7

Basic information

• Product Name: 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID
• Synonyms: 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID;3'-Amino-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid;Eltrombopag Intermediate 2;EltroMbopag I;3-(3-aMino-2-hydroxyphenyl)benzoic acid;[1,1'-Biphenyl]-3-carboxylic acid, 3'-aMino-2'-hydroxy-;3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC;Eltrombopag olamine Intermediate 1
• CAS NO: 376592-93-7
• Molecular Formula: C₁₃H₁₁NO₃
• Molecular Weight: 229.234
• EINECS: 1592732-453-0
• Mol File: 376592-93-7.mol
• Article Data: 17

Chemical Properties

• Melting Point: 222 °C(dec.)
• Boiling Point: 474.8±45.0 °C(Predicted)
• Appearance: /
• Density: 1.364
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 3.99±0.10(Predicted)
• CAS DataBase Reference: 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID(376592-93-7)
• EPA Substance Registry System: 3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID(376592-93-7)

Safety Data

• Hazardous Substances Data: 376592-93-7(Hazardous Substances Data)

Usage

Description

3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID, also known as Eltrombopag intermediate, is an organic compound derived from the hydrazine cleavage of Eltrombopag (E508000), a Thrombopoietin (Tpo) receptor agonist. It plays a crucial role in the synthesis of monoethanolamine salts and has potential applications in the pharmaceutical industry.
Used in Pharmaceutical Industry:
3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID is used as a key intermediate in the synthesis of monoethanolamine salts for the development of pharmaceutical compounds.
Used in Thrombocytopenia Treatment:
3''-AMINO-2''-HYDROXY-BIPHENYL-3-CARBOXYLIC ACID is used as a precursor in the production of Eltrombopag, an agonist of the Thrombopoietin (Tpo) receptor, which is utilized for the treatment of thrombocytopenia, a condition characterized by a low blood platelet count.

Upstream product

• 106-48-9 4-chloro-phenol 
• 58349-02-3 4-bromo-2-iodo-6-nitrophenol 
• 7693-52-9 4-bromo-2-nitrophenol 
• 106-41-2 4-bromo-phenol 
• 376591-94-5 2'-methoxy-3'-nitrobiphenyl-3-carboxylic acid 
• 95-85-2 2-hydroxy-5-chloro-aniline 
• 585-76-2 m-bromobenzoic acid 
• 64682-89-9 benzyl N-(2-hydroxyphenyl)carbamate 
• 56836-51-2 ethyl (2-hydroxyphenyl)carbamate 
• 88-75-5 2-hydroxynitrobenzene 
• 618-51-9 3-Iodobenzoic acid 
• 186663-74-1 tert-butyl (2-hydroxyphenyl)carbamate 

Downstream Products

• 376591-99-0 3’-{N’-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-di-hydropyrazol-4-ylidene]hydrazino}-2’-hydroxybiphenyl-3-carboxylic acid 
• 893736-72-6 2′-hydroxy[1,1-biphenyl]-3-carboxylic acid 

Relevant articles and documents

Preparation method of eltrombopag intermediate and preparation method of eltrombopag diethanolamine salt

The invention provides a preparation method of an eltrombopag intermediate and a preparation method of eltrombopag diethanolamine salt, and relates to the technical field of medicinal chemistry. According to the preparation method of the eltrombopag intermediate, p-bromophenol is taken as a raw material, and the problem of poor selectivity of nitration reaction is solved. After iodination, the coupling reaction yield of the intermediate compound as shown in a formula (I) and phenylboronic acid is high. Subsequently reduction reaction is carried out, the debromination reaction is complete, the yield is 90% or more, the refining is simpler, and the synthesis yield of the compound of the formula (I) is higher and the operation is simple. Through the improvement, the yield of the key compound shown as the formula (I) is relatively high, the subsequent treatment operation is simple, the process is easy for amplified production, the yield of the whole synthesis process of the eltrombopag diethanolamine salt is 48.1%, the operation is simple, less three wastes are generated, and the synthesis process is suitable for amplified production.

An improved process for the preparation of Eltrombopag Olamine and its intermediates

The present invention relates to an improved process for the purification of Eltrombopag olamine of compound of formula (2). The present invention also relates to an improved process for the preparation of Eltrombopag olamine intermediates and further conversion to Eltrombopag olamine of a compound of formula (2).

Synthetic method of eltrombopag intermediate and synthetic method of eltrombopag

The invention relates to the field of medicine synthesis, in particular to a synthesis method of an eltrombopag intermediate and a synthesis method of eltrombopag. The synthesis method of the eltrombopag intermediate comprises the following steps: mixing 2'-hydroxyl-3'-nitrobiphenyl-3-carboxylic acid or 5'-chloro-2'-hydroxyl-3'-nitrobiphenyl-3-carboxylic acid with an alkali, a catalyst and water,introducing hydrogen, and carrying out a hydrogenation reaction to form the eltrombopag intermediate. The synthesis steps are simplified, the generation of impurities is reduced, and the yield and purity are improved.